<DOC>
	<DOCNO>NCT02052024</DOCNO>
	<brief_summary>The present pilot study design assess extent BOTOX MYOBLOC cause muscle atrophy spastic patient . The primary objective ass whether statistically significant difference muscle atrophy two group one year period .</brief_summary>
	<brief_title>Myobloc Atrophy Study</brief_title>
	<detailed_description>Botulinum toxin long use clinical application treatment overactive skeletal smooth muscle , i.e . spasticity . The benefit botulinum therapy indisputable , however , muscle atrophy one main adverse effect may hinder patient 's strength decrease ability practitioner accurately administer botulinum toxin specific muscle group . This , turn may cause unintentional weakness adjacent muscle group inaccurate target diffusion botulinum toxin . Currently , two serotypes ( abbreviate BTX-A ( BOTOX , XEOMIN DYSPORT ) BTX-B ( MYOBLOC ) , respectively ) use clinical practice spasticity . Research show BTX-A BTX-B efficacious treatment spasticity . However , documented literature evaluate statistically significant difference degree muscle atrophy use BTX-A versus BTX-B .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>Men woman age 18 old spasticity secondary either disorder trauma , spinal cord injury ( SCI ) , brain injury , tumor , stroke , multiple sclerosis ( MS ) , peripheral nerve injury . Participants must ability provide write consent participate study . Patients receive BTXA BTXB past skeletal muscle group investigation patient allergic response BTXA BTXB past . Diagnosis Myasthenia gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis . Females pregnant breastfeeding . Subjects take Aminoglycosides agent interfere neuromuscular function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Modified Ashworth Scale</keyword>
	<keyword>MYOBLOC</keyword>
	<keyword>Botox</keyword>
	<keyword>Muscle Atrophy</keyword>
</DOC>